trending Market Intelligence /marketintelligence/en/news-insights/trending/PZKJH8AT9Utg6kQuaVOjAw2 content esgSubNav
In This List

US FDA approves Teva's newer asthma inhaler

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves Teva's newer asthma inhaler

The U.S. Food and Drug Administration approved Teva Pharmaceutical Industries Ltd.'s QVAR RediHaler, an inhaler for the maintenance treatment of asthma in patients aged 4 years and older.

The treatment eliminates the need for hand-breath coordination during inhalation, Teva said in a news release.

The approval was supported by data from a phase 1 study and four phase 3 studies.

The QVAR metered-dose inhaler with dose counter, the currently available form of the treatment, was approved by the U.S. FDA in 2014.

Teva plans to discontinue selling the current formulation of QVAR when the QVAR RediHaler is launched in the first quarter of 2018 in 40- and 80-micrograms strengths.